坏疽性脓皮病；治疗；生物制剂；JAK抑制剂," /> 坏疽性脓皮病；治疗；生物制剂；JAK抑制剂,"/> pyoderma gangrenosum,treatment,biological agents,JAK inhibitors,"/> 坏疽性脓皮病治疗进展

中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (3): 216-220.doi: 10.12144/zgmfskin20243216

• 综述 • 上一篇    下一篇

坏疽性脓皮病治疗进展

焦雨竹1,2,杨青1,2   

  1. 1山东第一医科大学附属皮肤病医院，山东济南，250022；2山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2024-03-15 发布日期:2024-02-28

Update of treatment of pyoderma gangrenosum

JIAO Yuzhu1,2, YANG Qing1,2   

  1. 1 Hospital for Skin Diseases, Shandong First Medical University, Jinan 250022, China；2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2024-03-15 Published:2024-02-28

PDF (PC)

118

摘要： 坏疽性脓皮病（PG）是一种以皮肤出现复发性、疼痛性及坏死性溃疡为特征的嗜中性皮病。目前尚无PG治疗的共识，且治疗困难。既往糖皮质激素为临床上常用的一线治疗药物，免疫抑制剂等其他传统药物可单独或联合糖皮质激素使用，但部分患者仍难以取得满意疗效。近年来生物制剂及小分子靶向药物逐渐应用于该病的治疗并取得了一定的疗效。本文主要对近年来治疗PG的生物制剂、JAK抑制剂等靶向药物的疗效和安全性进行综述，为临床治疗提供参考。

关键词: 坏疽性脓皮病；治疗；生物制剂；JAK抑制剂')">">坏疽性脓皮病；治疗；生物制剂；JAK抑制剂

Abstract: Pyoderma gangrenosum (PG) is a neutrophilic dermatosis characterized by recurrent, painful and necrotizing ulcers. There is neither consensus nor effective therapeutics on PG treatment at present, glucocorticoids were first-line treatment in clinical practice, immunosuppressants and other drugs can be used alone or in combination with glucocorticoids, but there's still difficulty achieving satisfactory results for some patients. Nowadays, biological agents and small molecule drugs have gradually applied to the treatment of PG and achieved certain effects. This review aims to summarize the efficacy and safety of targeted agents such as biological agents and JAK inhibitors to provide reference for clinical treatment.

Key words: pyoderma gangrenosum')">pyoderma gangrenosum, treatment, biological agents, JAK inhibitors